Northwest Biotherapeutics (NWBO) Depreciation & Amortization (CF) (2010 - 2026)

Northwest Biotherapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $771000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 77.65% year-over-year to $771000.0 in Q1 2026; TTM through Mar 2026 was $2.4 million, a 37.2% increase from a year earlier, with the FY2025 full-year figure at $2.1 million, up 18.35% from the prior year.
• Depreciation & Amortization (CF) advanced to $771000.0 in Q1 2026 per NWBO's latest filing, from $728000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $771000.0 in Q1 2026 and bottomed at $100000.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $434000.0 (2024), against an average of $432705.9.
• Across the five-year window, Depreciation & Amortization (CF) soared 580.52% in 2022 and sank 33.21% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $318000.0 in 2022, then surged by 33.33% to $424000.0 in 2023, then climbed by 3.07% to $437000.0 in 2024, then jumped by 66.59% to $728000.0 in 2025, then rose by 5.91% to $771000.0 in 2026.
• Per Business Quant, the three latest NWBO Depreciation & Amortization (CF) figures stand at $771000.0 (Q1 2026), $728000.0 (Q4 2025), and $451000.0 (Q3 2025).